Clinical Trial Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, Variants, or PubMed publications.

Have questions, comments, or suggestions? - Let us know!

Email us at : ckbsupport@genomenon.com

NCT ID NCT05428007
Title Interleukin-6 Receptor Inhibitor Sarilumab in Combination With Ipilimumab, Nivolumab and Relatlimab in Patients With Unresectable Stage III or Stage IV Melanoma
Recruitment Recruiting
Gender both
Phase Phase II
Variant Requirements No
Sponsors NYU Langone Health
Indications
Therapies
Age Groups: adult | senior
Covered Countries USA

Facility Status City State Zip Country Details
The Angeles Clinic at Cedars Sinai RECRUITING Los Angeles California 90025 United States Details
Massachusetts General Hospital RECRUITING Boston Massachusetts 02114 United States Details
Dana Farber Cancer Institute RECRUITING Boston Massachusetts 02215 United States Details
NYU Langone Health RECRUITING New York New York 10016 United States Details
*Shaded cells indicate that there was no data available from clinicaltrials.gov for the field